2020 April 21, 2020
Lynparza Gets NICE’s Stamp of Approval
1 min read
The National Institute for Health and Care Excellence has recommended Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation (see link below). NICE reported this endorsement is due to recent evidence from clinical trials. Using Kognitic‘s breadth of filters, our clients can access all Lynparza trials in this patient segment instantly!